Are GLP-1s Performance-Enhancing Drugs?

The use of GLP-1 medications, such as Ozempic and Wegovy, has sparked debate within the athletic community regarding their potential as performance-enhancing drugs. While these drugs are primarily prescribed for weight loss and managing type 2 diabetes, some experts suggest they could offer performance benefits to athletes. Serena Williams's return to tennis after using a GLP-1 medication has brought this issue to the forefront, though it is not confirmed she used it for performance enhancement. The World Anti-Doping Agency (WADA) has not yet classified GLP-1 agonists as prohibited substances, leaving a gray area for athletes considering their use. Some researchers point to potential improvements in endurance and recovery, while others argue that the primary effects are metabolic and not directly performance-boosting. The discussion highlights the evolving landscape of athletic enhancement and the challenges in defining what constitutes a performance-enhancing drug in the face of medical advancements.